Compositions for treating heart failure
Neuregulin protein administration addresses the limitations of current heart failure treatments by improving cardiac function and survival in selected patients, reducing mortality and readmissions.
Patent Information
- Application Number
- JP2024144148
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2011-11-02
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2032-10-08
AI Technical Summary
Current treatments for heart failure, such as ACE inhibitors and heart transplantation, are invasive, expensive, and limited in availability, necessitating the development of more effective and less invasive therapies.
Administration of neuregulin protein or its derivatives to patients with chronic heart failure, tailored through diagnostic tests to select suitable patients and administered in specific regimens to enhance cardiac function and survival.
Significant reduction in mortality, readmissions, and improvement in biomarker levels are observed in patients treated with neuregulin, indicating its potential as a promising treatment for heart failure.
Smart Images

Figure 2024160397000001 
Figure 2024160397000002 
Figure 2024160397000003
Abstract
Description
Detailed Description of the Invention
[0001] [1. Technical Field] The present invention relates to a method for preparing a medicament for preventing, treating or delaying heart failure in humans. Use of the regulin protein and the use of said agent in the prevention, treatment, or treatment of heart failure in humans In particular, the present invention relates to a method for the prevention or delay of neuregulin-induced inflammatory responses. The use of drugs to prevent, treat, or delay heart failure in specific populations of patients with chronic heart failure The present invention provides a method for
[0002] [2. Background technology] Approximately 5 million Americans suffer from heart failure, with more than 550,000 new cases each year. have been diagnosed with symptoms of heart failure. Current drug treatments for heart failure include dilating blood vessels and Angiotensin-converting enzyme (ACE), a vasodilator that lowers blood pressure and reduces the workload of the heart The mortality rate has decreased significantly, but the use of ACE inhibitors has The actual mortality reduction with the use of poliomyelitis is, on average, only 3-4% and there are no known potential side effects. There are further limitations associated with other options for preventing or treating heart failure. For example, heart transplants are significantly more expensive and invasive than medical treatments, and require the use of donor hearts. The use of mechanical devices such as biventricular pacemakers is also limited. Therefore, the development of new treatments that take into account the shortcomings of current treatments is essential. There is a need.
[0003] One promising new treatment is for people with or at risk of developing heart failure. Neuregulin (hereinafter referred to as "NRG") is administered to patients with N RGs are a family of EGF-like growth factors, consisting of NRG1, NRG2, NRG3, and NR A family of structurally related growth factors that includes G4 and their isoforms It contains a family of differentiation factors that mediate breast cancer cell differentiation and milk protein secretion. Stimulation of the neural crest cells, differentiation of Schwann cells, and acetylcholine receptors in skeletal muscle cells It is involved in a series of biological responses, such as stimulating the synthesis of endothelial cells and promoting cardiac cell survival and DNA synthesis. There are severe defects in ventricular trabecula formation and dorsal root ganglion development, and the neuregulin gene In vivo studies of gene-targeted homozygous mouse embryos have shown that neuregulins regulate the heart and nervous system. It has been shown to be essential for the development of the sect.
[0004] NRGs bind to the EGF receptor family, which is made up of EGFR , ErbB2, ErbB3 and ErbB4, which are involved in cell proliferation, cell They play important roles in multiple cellular functions, including differentiation and cell survival. , a protein tyrosine kinase receptor with an extracellular ligand-binding domain, a transmembrane kinase It consists of an enzyme domain and a cytoplasmic tyrosine kinase domain. ErbB3 or Erb After NRG binds to the extracellular domain of B4, it induces a conformational change, which leads to the formation of ErbB3 and ErbB4. Heterodimerization occurs between ErbB4 and ErbB2, or ErbB4 itself This results in the formation of a homodimer of the receptor, which binds the C-terminal domain of the receptor on the inner side of the cell membrane. The phosphorylated intracellular domain is then transported into the cell. In these cells, they bind to additional signaling proteins and activate the corresponding downstream AKT or ERK signaling proteins. This activates the neural pathway, triggering a series of cellular responses, such as: Stimulation or reduction of cell proliferation, cell differentiation, cell apoptosis, cell migration, or cell adhesion Among these receptors, ErbB2 and ErbB4 are the main receptors in the heart. is being expressed.
[0005] The EGF-like domain of NRG-1 (50 to 64 amino acids in size) Previous studies have shown that this is sufficient to bind and activate the receptors of Neuregulin-1β (NRG-1β) binds ErbB3 and ErbB4 with high affinity. It has been shown that the orphan receptor ErbB2 can directly bind to ErbB3. It binds ErbB3 and ErbB4 with higher affinity than the homodimers of ErbB1 and ErbB2. It can form heterodimers with ErbB4. Studies in neural development have shown that it is important for the formation of the sympathetic nervous system. We found that intact NRG-1β, ErbB2 and ErbB3 signaling pathways are required for the formation of ER-dependent endothelial cells. Targeted disruption of NRG-1β or ErbB2 or ErbB4 has been shown to improve cardiac function. Defective cardiac development leads to embryonic lethality. Recent studies have shown that it maintains normal cardiac function in adults. In addition, the roles of NRG-1β, ErbB2, and ErbB4 in cardiovascular development have also been reported. NRG-1β has been shown to enhance sarcomere organization in adult cardiac muscle. Recombinant NRG has been shown to be effective in clinical trials and in different animal models of heart failure. Administration of the EGF-like domain of β-1β significantly improved or suppressed the deterioration of myocardial function. These results support the use of NRG-1 as a potential therapeutic compound for the treatment of heart failure. However, there is no clear evidence that treatment with NRG-1 could provide long-term benefits to patients with heart failure. Whether these benefits can be provided to all patients with chronic heart failure or to a certain subset of patients More evidence is still needed as to whether the
[0006] 3. Summary of the Invention In a human clinical trial of neuregulin for the treatment of heart failure, Applicant is Assessment of the New York Heart Association (NYHA) functional class or NT-proBNP of the patient Or, by measuring plasma levels of BNP, we could determine whether patients received significant therapeutic benefit from neuregulin. We found that it is possible to select patients with heart failure who can receive treatment with a high mortality rate. This includes a wide decline.
[0007] Applicants believe that NRG mediates cardiomyocyte differentiation, sarcomere and cytoskeletal organization, and cellular function. The applicants have found that the compound enhances cell adhesion in clinical trials and in different clinical settings for heart failure. In animal models, NRG significantly improved or prevented the deterioration of myocardial function. Neuregulin, neuregulin polypeptide, and neuregulin were also found to significantly protect against Neuregulin derivatives, or compounds that mimic the activity of neuregulin, are within the scope of the present invention. is included.
[0008] In other words, in a first aspect of the present invention, a pharmaceutical composition comprising an effective amount of neuregulin is administered to treat chronic cardiac The pharmaceutical composition was administered for the treatment of patients with deficiencies, and the patients obtained significant benefits from the pharmaceutical composition. In some embodiments, the benefit is a significant reduction in mortality. and a significant reduction in re-hospitalization. In one embodiment, the benefit indicates improvement in chronic heart failure. In one embodiment, the pharmaceutical composition is an induction regimen. In an optimized embodiment, the induction regimen comprises administering to the patient the pharmaceutical composition The method includes administering the compound to a subject for at least 3, 5, 7, or 10 consecutive days. In embodiments, the pharmaceutical composition is administered at least 3, 6, or 12 days after the induction regimen. The drug is administered to the patient in a maintenance regimen for a period of one or more months. In an optimized embodiment, the regimen comprises administering the pharmaceutical composition for 3, 5, 7, or 10 days. This includes administering the drug every 24 hours.
[0009] In a second aspect, the present invention provides a method for improving survival or reducing mortality in patients with chronic heart failure. and administering to said patient a pharmaceutical composition containing an effective amount of neuregulin. In one embodiment, the pharmaceutical composition is administered to the patient in an induction regimen. In an optimized embodiment, the induction regimen comprises administering the pharmaceutical composition to at least one In some optimized embodiments, the method includes administering the compound for at least 3, 5, 7, or 10 consecutive days. The pharmaceutical composition is administered for at least 3, 6, or 12 months after the induction regimen. In an optimized embodiment, the patient is administered a controlled regimen. The method includes administering the pharmaceutical composition every 3, 5, 7, or 10 days.
[0010] In a third aspect of the present invention, a therapeutically effective amount of neuregulin is administered to the subject to administer a therapeutically effective amount of neuregulin to the subject. Treating patients with chronic heart failure whose plasma levels are within the favorable therapeutic range prior to treatment with neuregulin In one embodiment, the preferred therapeutic range is 4000 fmol / In another embodiment, the preferred therapeutic range is 1600 fmol / ml to In yet another embodiment, the preferred therapeutic range is between 1 In another preferred embodiment, the plasma level is less than 600 fmol / ml. It is measured by standard methods.
[0011] In a fourth aspect of the present invention, a therapeutically effective amount of neuregulin is administered to the patient in accordance with the NYHA cardiac function classification. It is therefore used to treat patients with chronic heart failure who have been classified into specific cardiac functional classes. In one embodiment, the specific cardiac function class is NYHA class II. In this embodiment, the particular cardiac function class is NYHA class III.
[0012] In a fifth aspect, the present invention provides a method for selecting a heart failure patient for treatment with neuregulin. This method involves measuring the plasma levels of NT-proBNP in the above patients. In one embodiment, a level of 4000 fmol / ml or less is a symptom of Neureg. In another embodiment, the patient is suitable for treatment of heart failure with 160 Levels between 0 fmol / ml and 4000 fmol / ml indicate neuregulin-induced cardiac failure. In yet another embodiment, the 1600 mol Levels of neuregulin below 1 / ml indicate that patients are suitable for the treatment of heart failure with neuregulin. is.
[0013] In a sixth aspect, the present invention provides a method for selecting a heart failure patient for treatment with neuregulin. This method is to evaluate the cardiac function class according to the NYHA cardiac function classification. In one embodiment, NYHA class II is a class of cardiac insufficiency caused by neuregulin. In another embodiment, the patient is in NYHA class III These results indicate that these patients are suitable candidates for the treatment of heart failure with neuregulin.
[0014] In a seventh aspect, the present invention provides a method for selecting a heart failure patient for treatment with neuregulin. In one embodiment, the diagnostic kit is for detecting N in a patient with heart failure. Contains immunoassay reagents for measuring plasma levels of T-proBNP, 4000 fmol A level of neuregulin below 1 / ml indicates that patients are suitable for heart failure treatment with neuregulin. In another embodiment, the level is between 1600 fmol / ml and 4000 fmol / ml. These results suggest that these patients are suitable candidates for the treatment of heart failure with neuregulin. In this embodiment, a level of 1600 mol / ml or less indicates that neuregulin is treating heart failure. This indicates that the patient is a good candidate for treatment.
[0015] In an eighth aspect of the present invention, there is provided a use of a neuregulin protein for the preparation of a medicament. These drugs can be administered to patients with chronic heart failure for long-term benefit. In one embodiment, the long-term benefit is improved survival. The long-term benefit is reduced re-hospitalization. In another embodiment, the long-term benefit is reduced In one embodiment, the drug is an improvement in a biomarker that indicates long-term prognosis of chronic heart failure. The agent is administered to the patient in an induction regimen. The regimen involves administering the drug for at least 3, 5, 7, or 10 consecutive days. In an optimized embodiment, the agent is administered at least 3, 6, or 1 day after the induction regimen. The patient is administered a controlled regimen for two months. The management regimen involves administering the above drugs every 3, 5, 7, or 10 days. .
[0016] In a ninth aspect of the present invention, there is provided a method for treating chronic heart failure with a neuregulin protein. A companion diagnostic test was provided: N-terminal pro-brain natriuretic peptide (NT- proBNP) will be used as a biomarker for the companion diagnostic test. In some embodiments, a level of 4000 fmol / ml or less is indicative of neuregulin-induced heart failure. In another embodiment, the patient is suitable for treatment. Levels between 4000 and 4000 fmol / ml are appropriate for patients who are suitable for the treatment of heart failure with neuregulin. In yet another embodiment, the level of 1600 mol / ml or less is These results indicate that these patients are suitable candidates for the treatment of heart failure with neuregulin.
[0017] In a tenth aspect of the present invention, a method for treating chronic heart failure using neuregulin is provided. The method includes a pre-treatment evaluation procedure, and each patient is assigned to receive a new In one embodiment, the evaluation determines whether a person is suitable to receive regulin therapy. The procedure includes NYHA functional classification of the patient with chronic heart failure. The evaluation procedure included testing of plasma NT-proBNP or plasma BNP in each patient with chronic heart failure. I am.
[0018] In an eleventh aspect of the present invention, a patient with chronic heart failure is suitable for neuregulin protein treatment. A companion diagnostic kit for determining whether the patient has a pulmonary circulation disorder is provided. Diagnostic kits include plasma NT-proBNP or plasma BNP test kits, and the above kits. According to the usage and test results, patients are suitable for Neuregulin protein therapy. It includes a description of how to determine whether
[0019] 4. Detailed Description of the Invention For clarity of disclosure, and not by way of limitation, the following detailed description of the invention is given below. All publications mentioned herein are incorporated by reference in their entirety. by reference to disclose and describe the methods and / or materials involved in the This is incorporated herein by reference.
[0020] A.Definition Unless otherwise defined, all technical and scientific terms used herein are Terms have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. All patents, applications, published applications, and other information cited herein are the property of their respective owners. The publications described in this section are incorporated herein by reference in their entirety. Definitions are set forth in the patents, applications, published applications, and the like which are incorporated by reference herein. In cases where there is a contradiction or inconsistency with definitions set forth in other publications, The definitions set forth take precedence over the definitions incorporated herein by reference.
[0021] As used herein, the singular forms "a," "an," and "the" refer to Unless the context clearly dictates otherwise, use "at least one" or "one or more It means "number".
[0022] As used herein, "neuregulin" as used in the present invention or "NRG" means a compound that binds to ErbB2, ErbB3, ErbB4, or a combination thereof. represents a protein or peptide that can be activated, and all neuregulin isoforms form, neuregulin EGF-like domain alone, and neuregulin EGF-like domain included Polypeptides, neuregulin mutants or derivatives, and the like that activate the above-mentioned receptors The term "neuregulin-like gene product" includes any type of neuregulin-like gene product that activates the neuregulin-like protein (details are provided below), but is not limited to this. Neuregulin also includes, but is not limited to, NRG-1, NRG-2, NRG Mimicking the activities of NRG-3 and NRG-4 proteins, peptides, fragments, and neuregulins The neuregulin used in the present invention includes compounds that inhibit the above-mentioned ErbB receptor. It can activate receptors and regulate their biological responses. For example, in skeletal muscle cells, stimulates the synthesis of acetylcholine receptors in cardiac cells and / or promotes cardiac cell differentiation, survival and Increases DNA synthesis. Neuregulins also do not substantially alter their biological activity. Also included are those variants having conservative amino acid substitutions that do not alter the amino acid sequence. Conservative substitutions are known to those of skill in the art and are intended to enhance the biological activity of the resulting molecule. Those skilled in the art will generally recognize that non-essential amino acids of a polypeptide can be made without modification. It was found that single amino acid substitutions in the target region did not substantially alter biological activity. (For example, Watson et al. Molecular Biology of the Gene, 4th Edition, 1987, (See The Bejacmin / Cummings Pub. Co., p. 224.) In a preferred embodiment, the present invention The neuregulin used in this study is ErbB2 / ErbB4 or ErbB2 / Erb The peptide binds to and activates the bB3 heterodimer. Column:SHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCPN NRG-1β2, including EFTGDRCQNYVASFYKAEELYQ (SEQ ID NO: 1) By way of limitation, peptides containing residues 177-237 of the isoform are included. The above peptide containing residues 177-237 of the NRG-1β2 isoform is not intended to be a The EGF-like peptides shown to be sufficient to bind and activate the receptors Includes the domain.
[0023] As used herein, "epidermal growth factor-like domain" or "EGF-like domain" refers to "ErbB2, ErbB3, ErbB4, or a combination thereof, binds to and activates them. The EGF receptor binding domain is structurally similar to that of the EGF receptor binding domain disclosed in The polypeptide motifs encoded by the neuregulin gene are WO 00 / 64400, Holmes et al., Science, 256:1205-1210 (1992); US Patent Nos. 5,530,109 and 5,716,930; Hijazi et al., Int. J. Oncol., 13:1061-1067 (1998) ; Chang et al., Nature, 387:509-512(1997); Carraway et al., Nature, 387:512-516 (1997); Higashiyama et al., J. Biochem., 122:675-680 (1997); and WO 97 / 09425. The entire contents of these documents are incorporated herein by reference. The EGF-like domain is a heterodimer of ErbB2 / ErbB4 or ErbB2 / ErbB3. In one embodiment, the EGF-like domain binds to and activates the chromosome dimers. In one embodiment, the amino acid sequence of the receptor binding domain of NRG-1 is included. The EGF-like domain is located at 177-226, 177-237, or 177- In one embodiment, the E The GF-like domain contains the amino acid sequence of the receptor binding domain of NRG-2. In an embodiment, the EGF-like domain has the amino acid sequence of the receptor binding domain of NRG-3. In one embodiment, the EGF-like domain comprises a receptor-binding domain of NRG-4. In one embodiment, the EGF-like domain comprises an amino acid sequence of As described in US Patent No. 5,834,229, Ala Glu Lys Glu L ys Thr Phe Cys Val Asn Gly Gly Glu Cys Phe Me It contains the amino acid sequence tValLysAspLeuSerAsnPro.
[0024] The neuregulin protein is preferably in the form of a pharmaceutical composition, The dosage and route of administration can be determined according to methods known in the art. (See, for example, Remington: The Science and Practice of Pharmacy, Alfonso R. Gennaro (E Mack Publishing Company, April 1997; Therapeutic Peptides and Proteins: F ormulation, Processing, and Delivery Systems, Banga, 1999; and Pharmaceutical Fo rmulation Development of Peptides and Proteins, Hovgaard and Frkjr (Ed.), Taylor & Francis, Inc., 2000; Medical Applications of Liposomes, Lasic and Papahadjopou los (Ed.), Elsevier Science, 1998; Textbook of Gene Therapy, Jain, Hogrefe & Hub er Publishers, 1998; Adenoviruses: Basic Biology to Gene Therapy, Vol. 15, Seth , Landes Bioscience, 1999; Biopharmaceutical Drug Design and Development, Wu-Pon g and Rojanasakul (Ed.), Humana Press, 1999; Therapeutic Angiogenesis: From Basi c Science to the Clinic, Vol. 28, Dole et al. (Ed.), Springer-Verlag New York, 1 (See 999).
[0025] The neuregulin protein can be administered orally, rectally, topically, by inhalation, or by buccal administration. Oral administration (sublingual administration, etc.), parenteral administration (subcutaneous administration, intramuscular administration, intradermal administration, or intravenous administration, etc.) ), transdermal, or other suitable routes of administration. The optimal route in any given case will depend on the nature and severity of the condition being treated and the specific It depends on the nature of the neuregulin protein. Alternatively, the neuregulin protein can be administered in a pharma- ceutical carrier. It is preferred to administer the compound in combination with a carrier or excipient. In this manner, any suitable pharma- ceutically acceptable carrier or excipient may be used. Any suitable carrier or additive may be used (see Remington: The Science and Practice ice of Pharmacy, Alfonso R. Gennaro (Editor) Mack Publishing Company, April 1997 etc.).
[0026] According to the present invention, the neuregulin protein is administered alone or in combination with other agents, carriers or Together with additives, it can be administered by intracavernous injection, subcutaneous injection, intravenous injection, intramuscular injection, intradermal injection, or oral administration. The composition may be formulated for any suitable route of administration, such as oral or topical administration. A formulation for injection in a unit dose form in an ampoule or multi-dose container containing The formulation may be in the form of a suspension, solution, or emulsion in an oily or aqueous vehicle. The composition may contain formulation agents such as suspending agents, stabilizing agents, and / or dispersing agents. The active ingredient should be mixed with a suitable vehicle, sterile pyrogen-free water, or other suitable preparation prior to use. It may be in powder form to be made into a solution. Topical administration in the present invention may be in the form of foam, gel, cream, Ointments, skin patches, or pastes may be used.
[0027] Pharmaceutically acceptable compositions that may be used in the present invention, and methods of administering the same, are disclosed in U.S. Pat. ,736,154;6,197,801B1;5,741,511;5,886,039 5,941,868; 6,258,374B1; and 5,686,102. This includes, but is not limited to, those that are
[0028] The therapeutic or prophylactic dosage will vary depending on the severity of the condition to be treated and the route of administration. The dosage, and perhaps the frequency of administration, will vary depending on the age, weight, condition, and response of the individual patient. It changes to:
[0029] Your doctor will determine how and when to stop or discontinue treatment due to toxic or adverse effects. Know whether to discontinue treatment or adjust treatment to a lower dose. Conversely, the attending physician may decide to discontinue treatment at any time if the clinical response is not sufficient (excluding toxic side effects). We also recognize that treatment may need to be adjusted to a higher dose, such as:
[0030] Any suitable route of administration may be used. This includes tablets, wafers, dispersions, suspensions, solutions, capsules, salves, etc. According to conventional drug synthesis techniques, in practical use, The neuregulins alone or in combination with other drugs may be used as active ingredients in a mixture: β-Cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, etc. The carrier may be combined with a pharmaceutical carrier or excipient such as the above-mentioned, for example, topical or parenteral administration. For parenteral administration, such as intravenous injection or infusion, In preparing the composition, water, glycols, oils, buffers, sugars, preservatives, liposomes, etc. Similar pharmaceutical vehicles known to those skilled in the art may be used. Such parenteral compositions include, for example, , 5% w / v dextrose, normal saline, or other solutions. These include, but are not limited to, the following: The total dose of the neuregulin protein is administered in an amount of about 1 to 2000 ml of intravenous fluid. The amount of diluent will vary depending on the total dose.
[0031] The present invention also provides kits for carrying out the therapeutic regimens of the present invention. is administered in a pharma- ceutically acceptable form in a therapeutically effective amount, either alone or in combination with other drugs. The preferred dosage form is a non-medicinal drug. Bacterial saline, dextrose solution, buffer, or other pharma- ceutically acceptable sterile fluid The composition may be lyophilized or dried, In this case, the kit is sterile in order to reconstitute the compound to make an injectable solution. The container may further contain a pharma- ceutically acceptable solution, preferably a pharma- ceutically acceptable solution. Examples of suitable solutions include saline and dextrose solution.
[0032] In another embodiment, the kit of the present invention is packaged in a sterile form for injection of the composition. needles or syringes, preferably wrapped in paper, and / or wrapped alcohol pads. It further includes instructions for administration of the composition by a physician or a patient. Good too.
[0033] As used herein, "treat," "treatment," and "treating" refer to the treatment of a disease. any method of ameliorating or otherwise altering for the better the symptoms of an illness or disease The effectiveness of a treatment can be measured in terms of completely or partially preventing a disease or its symptoms. and / or for the prevention of a disease and / or harmful effects resulting from said disease. Treatment may be therapeutic in the sense of partial or complete healing. Treatment may include administration of any of the compositions herein. The pharmaceutical uses of
[0034] As used herein, "heart failure" refers to the inability of the heart to pump blood at the rate required by metabolic tissues. Heart failure refers to an abnormality in the function of the heart that does not pump blood. A wide range of conditions including tachycardia, familial hypertrophic cardiomyopathy, ischemic heart disease, idiopathic dilated cardiomyopathy, and myocarditis The heart failure includes, but is not limited to, ischemic, congenital, rheumatoid arthritis, and other heart disease conditions. It can result from many causes, including bacterial, viral, toxic or idiopathic forms. Cardiac aneurysm is a serious disease state that is a precursor to congestive heart failure and cardiac arrest.
[0035] As used herein, "protein" refers to any molecule that is capable of functioning in a particular organism, unless the context clearly dictates otherwise. Unless otherwise specified, it is synonymous with "polypeptide" or "peptide."
[0036] As used herein, "plasma" means plasma, unless the context clearly dictates otherwise. It is synonymous with "serum."
[0037] As used herein, a "long-term benefit" refers to a condition that persists after a treatment or intervention. This represents a benefit that cannot be seen in the short term due to intervention. Long-term benefit would be improved survival, reduced re-hospitalization, or a biomarker that indicates long-term prognosis. In one embodiment, the time period for observing the benefit is about 6 months. In one embodiment, the period of time for observing the benefit is about one year. The period of time for observing said benefits is about 2 years. In other embodiments, the period of time for observing said benefits is about is about 3, 5, 10 or more years.
[0038] As used herein, "survival" refers to the duration or probability that a patient is alive. The time course of treatment is determined by the severity of the disease and may be expressed as survival time or survival rate. Survival time is the time from diagnosis or treatment to death. Survival rates are the percentage of people who are alive at a given time after diagnosis or treatment. For each patient, any increase in survival time due to a treatment or intervention is considered a benefit. For a patient population or large population, it can be considered an increase in average survival time or Increased survival rates can be considered a benefit.
[0039] As used herein, "readmission" refers to the number of times a patient is admitted to a hospital within a certain period of time. Hospital admissions can be for any disease, but For each patient, the disease may be due to the same disease as that being treated. A reduction in the number of readmissions can be considered a benefit for a patient population or large population. ,A reduction in the total or average number of readmissions can be considered a benefit.
[0040] As used herein, "N-terminal brain natriuretic peptide" or "NT-p "roBNP" refers to inactive residual N-terminal proBNP, the latter of which is mainly secreted from the myocardium of the left heart wall. It is a prohormone of BNP, a hormone-active natriuretic peptide released from cells. In response to the stretch and tension of the myocardial wall, the prohormone proBNP is proteolytically degraded. Upon cleavage, it is separated into BNP and the hormone-inactive residue NT-proBNP.
[0041] BNP and NT-proBNP plasma levels are important in patients with suspected or established heart failure. These are promising items for the daily management of patients with glaucoma. Most studies on the use of NP have addressed its diagnostic properties. More and more evidence is available to support the prognostic value of T-proBNP. NT-proBNP has a half-life in the blood that is approximately six times longer than BNP, making it a useful diagnostic tool for heart failure. Plasma NT-proBNP levels are more widely used as a diagnostic or prognostic marker. For example, the kits from Roche or Biomedica are available. Examples of the commercially available kit include, but are not limited to, a kit from the company NT- ProBNP levels were detected by a kit from Biomedica (Austria). It was.
[0042] Blood levels of BNP and NT-proBNP were both markers in patients with poor prognosis. It is used for screening and diagnosing heart failure because the levels of In the present invention, BNP or NT-proBNP is useful for determining the prognosis of heart failure. They found that plasma levels of neuregulin indicate patients suitable for treating heart failure with neuregulin. Indeed, any diagnostic or prognostic marker of heart failure would be indicative of whether a patient is receiving neuregulin therapy for heart failure. The NT-p identified in the present invention can be used to determine whether a patient is suitable for treatment with the roBNP plasma levels indicate that heart failure patients would gain significant therapeutic benefit from neuregulin They should be used as guidelines rather than limitations for the selection of Using plasma levels of 5000 fmol / ml, neuregulins are able to provide therapeutic benefit. It is still possible to select patients with heart failure who are more likely to receive treatment, but some of these patients may need more Some patients may derive less benefit from treatment.
[0043] As used herein, the "New York Heart Association" or "NYHA" Cardiac Function The classification is a simple way of classifying the severity of heart failure. This classification determines the degree of limitation ( The limitation / symptoms relate to the degree of change in normal breathing and shortness of breath and / or severe pain Patients were divided into four categories based on the degree to which they experience symptoms during normal physical activity (I, symptoms during normal physical activity and no limitations (e.g., shortness of breath when walking or climbing stairs); II, mild symptoms ( mild shortness of breath and / or pain) and mild limitation during usual activities; III, usual Symptoms limit activity even when performing sub-intensity activities (e.g., walking short distances (20-100 m)) The patient is severely restricted and symptoms are only stable when resting. IV, many patients are bedridden and resting Symptoms also appear in the hands and feet, causing significant limitations.
[0044] As used herein, an "activity unit," "EU," or "U" is the maximum reaction This means the amount of standard that can induce 50% of the active unit for a given active substance. To determine the EC50, the EC50 should be measured. If the EC50 of the test was 0.1 μg, this would be 1 unit. If 1 μg of the product is used, 10EU (1 / 0.1) is used. EC50 can be determined by any method known in the art and has been used by the inventors The determination of the active units includes the determination of the active units of the genetically engineered products and This is important in the quality control of drugs used in clinical practice. Therefore, products from different formulations and / or different batch numbers can be manufactured to the same standard. It can be quantified by:
[0045] The following shows the binding of NRG to cell surface ErbB3 / ErbB4 molecules and ErbB2 ligand. An exemplary, rapid method for determining the biological activity of NRG-1 via indirect mediation of phosphorylation. It is a sensitive, flexible, and quantitative method (Michael D. Sadick et al., 1996, Analytical Biochemistry, 235:207-214 and WO03 / 099300, etc.).
[0046] Briefly, it is called Kinase Receptor Activity Enzyme-Linked Immunosorbent Assay (KIRA-ELISA). The assay involves two separate microtiter plates. Titer plates are for cell culture, ligand stimulation, and cell lysis / receptor solubilization and the other microtiter plate for receptor capture and phosphotyrosine ELISA. The assay was performed to measure NRG-induced IL-1 expression in the adherent breast cancer cell line, MCF-7. Analysis of ErbB2 activity was performed using intact receptor stimulation. Proteins were solubilized via Triton X-100 lysis and the receptors ErbB3 or ELISA coated with ErbB2-specific antibody that does not cross-react with ErbB4 The degree of receptor phosphorylation was measured by anti-phosphotyrosine ELISA. A reproducible standard curve was developed for heregulin β1(177-244). Created with an EC50 of approximately 360 pM. Ideal HRGβ1(177-244) sample However, KIRA-ELISA and quantitative anti-phosphotyrosine Western blot analysis When the two methods are used for analysis, the results show a high degree of correlation with each other. The above-mentioned assay method is based on the ERK signaling pathway mediated by the interaction of HRG with ErbB3 and / or ErbB4. Tyrosine phosphorylation of rbB2 can be clearly quantified.
[0047] Since most genetically engineered drugs are proteins and polypeptides, their activity is The evaluation is based on the amino acid sequence or the active center formed by its three-dimensional structure. The activity titer of proteins and polypeptides does not correspond to their absolute amount. Activity can be evaluated in weight units, like the weight units of chemicals. However, the biological activity of genetically engineered drugs is generally not consistent with their pharmacodynamic properties. Also, the potency unit is calculated by the potency determination system established through a given biological activity. Therefore, the assessment of biological activity can be done by determining the potency of a biologically active substance. It can be part of the measurement process and is an important element of the quality control of genetically engineered medicines. For the quality control of manufactured products and clinically used drugs, biological activity criteria are Making decisions is important.
[0048] The amount of a standard that can induce 50% of the maximum response is defined as an activity unit (1 EU). Therefore, different formulations and products from different batch numbers can be manufactured to the same standard. It can be quantified by:
[0049] B. Working Example Example 1: Survival of rats with CHF following different routes of Neucardin™ administration Effect on survival rate introduction In this study, we used a coronary artery ligation (CAL)-induced CHF model to investigate the effect of microinjection. Neucar administered by IV infusion using an injection pump or by subcutaneous (SC) bolus. The effect of administration of din on survival and cardiac hemodynamics was evaluated from CAL to The study was conducted 120 days after Neucardin administration, which began 4 weeks after the first administration. Echocardiography and cardiac remodeling to confirm function and recovery from CAL was also used.
[0050] 2. Method 2.1. Test animals: Strain, origin: Wistar rats, Shanghai SLAC Laboratory Animal CO. LTD; Weight 200±10g, male; 2.2 Test Subjects 2.2.1 Neucardin(TM) ID: Recombinant human neuregulin-1 for injection (rhNRG-1, Neucardin( trademark)) Lot number: 200607009 Manufacturer:Zensun (Shanghai) Sci & Tech Co., Ltd Dosage form: Lyophilized powder Appearance: White or off-white cake Labeled dose of rhNRG-1: 250 μg / vial Specific activity: 4897U / vial Storage conditions: 2~8℃ 2.2.2 Excipients: ID: placebo of recombinant human neuregulin-1 Dosage form: Lyophilized powder Appearance: White or off-white cake Composition: Human serum albumin, mannitol, phosphate, sodium chloride Storage conditions: 2~8℃ 2.3 Steps: 2.3.1 Method for creating a rat CHF model The LAD of rats was ligated. Briefly, ketamine hydrochloride (100 mg / kg, I Rats were anesthetized with 100 mL of 10 ... Oxygen was mechanically supplied by air (respiratory rate: 60 breaths / min, tidal volume: 20 ml). A left thoracotomy was performed between the fourth and fifth intercostal spaces, and the skin was incised along the left sternal line. The 4th rib was resected toward the sternum. The pericardial sac was punctured to expose the heart. Silk suture The LAD was ligated at a point approximately 2 mm from the origin using a 6-0 catheter. The rat was then deflated and the chest was closed in three layers (ribs, muscle, and skin). The rats were then allowed to resume their normal activities and returned to their cages after the anesthesia had worn off. If the EF value is 30-45%, a formal test is required. All rats in each group were housed in five cages and had free access to standard chow. The room temperature was kept at 21±1°C, and the light / dark cycle was 12 hours. Switched the dark.
[0051] 2.3.2 IV infusion using a microinjection pump IV infusion of vehicle or Neucardin™ was administered via the tail vein. To carry out the procedure, a rat restrainer appropriate for the weight of the rat was used. The rat was placed near the restrainer and gently placed in the apparatus. Usually, the rat entered the restrainer without assistance. The animals were then moistened with alcohol to increase blood flow in the tail veins and to soften the stratum corneum of the skin. The rat's tail was wiped with gauze soaked in water. The two lateral tail veins were identified and inserted into the bevel of the needle. Insert the needle into the tail vein 2-3 cm from the end of the tail with the needle pointing upwards so that it is roughly parallel to the vein. The needle was inserted 2 mm into the tail vein. The needle tip was then inserted into the tail vein. Blood was drawn from the needle into the tail. The needle was fixed to the tail using medical tape. 2-0.4ml / hour) and administer the drug via microinjection pump or bolus injection. or vehicle infusion was initiated.
[0052] 2.3.3 SC bolus A SC bolus of vehicle or Neucardin™ was administered into the rat's back. To carry out this procedure, a rat restrainer appropriate for the weight of the rat was used. The rat's back was wiped with alcohol-moistened gauze to disinfect the skin. Insert the needle 3-4 cm subcutaneously into the rat's back with the needle pointing upwards and nearly parallel to the skin. The needle was then secured to the patient's back using medical tape and connected to an irrigation tube. After that, the rat was placed near the restrainer and gently placed in the device. Normally, rats were restrained without assistance. The patient entered the container. After the retainer was closed, the bolus injection was started.
[0053] 2.3.4 Experimental groups and drug infusions The MI rats were randomly divided into four groups according to their EF values:
[0054] Group A (control experiment with IV and SC bolus): n=58 rats, microinjection The vehicle was administered by IV infusion via an injection pump at a rate of 0.2 ml per day for 8 hours for the first 10 days. / hr speed and administering a SC bolus of excipient (same amount as Neucardin™). The treatment was administered every 5 days until the 120th day.
[0055] Group B (Neucardin™ SC bolus): n=58, microinfusion The vehicle was administered by IV infusion via injection pump for 8 hours daily for the first 10 days at a dose of 0.2 ml. 1 / hr and a SC bolus of Neucardin™ (10 μg / day) was administered every 5 days until the 120th day.
[0056] Group C (Neucardin™ IV infusion): n=57, microinjection Neucardin™ IV infusion (0.625 μg / kg / day) via injection pump The first 10 days were followed by 8 h of SC injections at a rate of 0.2 ml / h. A bolus (same amount as Neucardin™) was administered every 5 days until the 120th day.
[0057] Group D (Neucardin™ IV infusion and SC bolus): n=57 , IV infusion of Neucardin™ via a microinjection pump (0. 625μg / kg / hour) at a rate of 0.2ml / hour for 8 hours daily for the first 10 days. and administering a SC bolus of vehicle (same amount as Neucardin™) on days 1, 6, and 7. Neucardin™ administered on day 11, then every 5 days from day 16 through the final day A SC bolus of 10 μg / day was administered.
[0058] 2.3.5 Acquired Data Survival rate; echocardiography parameters; hemodynamic parameters; 3. Results 3.1 Survival rate Table 1 shows the survival rates among the groups. The survival rates were as follows: Group A (IV point of vehicle) drops and SC bolus), 48.3%, and Group B (Neucardin™ S C bolus) and 62.1% in group C (Neucardin™ IV infusion). Group D (IV infusion and SC bolus of Neucardin™) was 64.9%; ) was 82.5%. The survival rate or mean survival time of dead rats in groups B, C, and D showed improvement or duration longer than Group A, with Group D showing the greatest effect.
[0059] [Table 1]
[0060] 3.2 Echocardiography parameters Echocardiography parameters are shown in Table 2. Four weeks after coronary artery ligation and at study Before administration of the substances, the CHF rats were randomly divided into four groups according to the EF values. As shown in the figure, there was no significant difference between the four groups before treatment (BT). After that, EF values were 30.7 ± 3.1 in the vehicle group and 30.7 ± 3.1 in the SC bolus group, respectively. In the Neucardin group, it was 32.9 ± 4.1, whereas in the IV infusion of Neucardin 33.5 ± 3.4 in the rdin™ group, and 33.5 ± 3.4 in the IV infusion and SC bolus groups. In the Neucardin™ group, it was 36.2 ± 4.8. The EF and FS values of groups B, C, and D were higher than those of group A. It was.
[0061] [Table 2]
[0062] 3.3 Hemodynamic parameters Table 3 shows the MAP, HR, ±dp / dt of the four groups of anesthetized animals on day 121. , LVEDP, and LVSP measurements are shown. C Administered either by bolus or IV infusion (Groups B and C ), and Neucardin™, compared with Group A, improved dp / dt by 19 .6% and 27.1%, and -dp / dt by 22.5% and 29.8%, respectively. Neucardin™ was administered by both IV infusion and SC bolus. In group D, mean arterial pressure (MAP, 1 12.3±5.5mmHg), left ventricular systolic pressure (LVSP, 139.4±9.8mmHg ), +dp / dt(7012.1±903.0mmHg / sec), -dp / dt(-435 MAP, 3.2±847.6mmHg / sec) was significantly increased. These values of LVSP, +dp / dt, and -dp / dt were obtained from rats receiving vehicle. These were 10.6%, 9.2%, 38.5%, and 37.5% higher than those of the control group, respectively. These results showed that groups B, C, and D were significantly superior to group A in terms of hemodynamic parameters. The results showed that group D was more effective than group D.
[0063] [Table 3]
[0064] [Table 4]
[0065] 4. Conclusion In the case of combined administration of Neucardin™ by IV infusion and SC bolus Whether the peptide was administered by only one route or not, the subjects were treated with vehicle. The survival rate of rats in which CHF was induced by CAL was higher than that of rats in which CHF was induced by CAL alone. and improved cardiac function parameters.
[0066] Example 2: Recombinant Human Neuregulin 1 in Patients with Chronic Heart Failure Based on Standard of Care A randomized, double-blind, multicenter, placebo-controlled study to evaluate efficacy and safety To evaluate the effect of recombinant human neuregulin-1 infusion in chronic heart failure, standard A treatment-based, phase II, double-blind, multicenter, placebo-controlled, standard of care-based trial The study was conducted at multiple clinical sites in China. A total of 195 patients with NYHA class II or III Stable patients with chronic heart failure were admitted to hospital and assigned to one of three groups: placebo, 0.6 μg / kg The groups were randomly assigned to receive either 1.2 μg / kg rhNRG-1 or 1.2 μg / kg rhNRG-1. There were no significant differences in demographics or treatment history between the two groups. Patients were administered the drug for 10 consecutive days in the hospital and were discharged after the 11th follow-up. Another on-site follow-up was performed on days 30 and 90 since the last patient was admitted. A telephone interview was conducted one year later.
[0067] Investigational Drug: Specifications: Neucardin (trademark), molecular weight of 7054 Dal (1 μg = 0.14 nm ol) neuregulin-1 β2 isoform containing the 61 amino acid sequence that contains the EGF-like domain Acid polypeptide. 250μg(5000EU) / vial (1μg=20EU).
[0068] Preparation: For injection.
[0069] Administration form: Infusion.
[0070] Storage: 3-8°C, in a safe place with limited access and no light.
[0071] placebo: Specifications: Neucardin™ excipient (active recombinant human neuregulin-1 protein) (250 μg / vial, protein-free).
[0072] [Table 5]
[0073] Test procedure Criteria for study participants included relatively stable disease (no clinical signs, symptoms, or symptoms for more than one month) LVE (including those receiving standard treatment for CHF at target or maximum tolerated doses) Patients with CHF (NYHA class II or III) between 18 and 65 years of age with F less than 40% The main exclusion criteria were: acute myocardial infarction, hypertrophic cardiomyopathy, constrictive pericarditis, severe Valvular or congenital heart disease, severe pulmonary hypertension, systolic blood pressure less than 90mmHg or systolic blood pressure higher than 160 mmHg, severe arrhythmia, or cardiac arrest within the past 6 months Women who had undergone surgery or had a cerebrovascular event, were claustrophobic, or were pregnant were included. All patients signed a consent form.
[0074] Placebo or rhNRG-1 (0.6 or 1.2 μg / kg / day) for 10 consecutive days Patients were randomly assigned to one of three groups to receive 10 mg of 10 ... Two separate follow-up visits were conducted on the 30th and 90th days. Blood samples were collected from each patient on days 1, 30, and 90. NT-proBNP was measured at the core laboratory using a Biomedica kit. A telephone interview was conducted to collect information on readmissions one year after the last patient was admitted. The researchers conducted interviews and recorded all telephone interviews on a special form signed by the researchers. Ta.
[0075] Of 48 patients in the placebo group with available readmission information, 12 (25.0%) patients were re-hospitalized at least once due to worsening heart failure. In the / kg group, only 4 of 46 patients (8.7%) were readmitted to the hospital. (P = .05 compared with placebo); readmission rate in the 1.2 μg / kg group was 2 The mean number of readmissions was 1.0% (11 / 50) in the placebo group. The mean mean was 0.458 (22 / 48) in the 0.6 μg / kg group (8 / 41) and 1 In the 0.2 μg / kg group (19 / 50), the mean number of re-hospitalizations was significantly lower than in the placebo group. This was a decrease of 57.4% and 17.0%, respectively.
[0076] In the placebo group, NT-proBNP levels remained almost constant throughout the study compared with baseline. On day 11, NT-proBNP was significantly higher in the rhNRG-1 group. In the 0.6 μg / kg group, the mean serum creatinine concentration increased from 1853 ± 1512 to 2399 ± 1841. fmol / ml, P<0.01; 1.2 μg / kg group, 1562 ± 1275 from 0.01 to 2774±1926 fmol / ml, P<0.01). However, this increase was temporary. This is not due to a deterioration in cardiac function, as cardiac function has improved. NT-proBNP was significantly higher at 30 and 90 days in the 1.2 μg / kg group. Furthermore, in the 0.6 μg / kg group, In comparison, NT-proBNP was 1323 ± 1124 fmol / ml at day 30 (P = 0 .01) and at 90 days (1518 ± 1403 fmol / ml, P = 0.01). It has decreased.
[0077] These results suggest that treatment with rhNRG-1 reduces hospital readmissions and increases NT-proBNP. rhNRG-1 provides long-term benefit to patients with chronic heart failure by lowering plasma levels It showed that it can be done.
[0078] Example 3: Recombinant Human Neuregulin 1 in Patients with Chronic Heart Failure Based on Standard of Care Randomized, double-blind, multicenter, placebo-controlled survival study To evaluate the effect of recombinant human neuregulin-1 infusion in patients with chronic heart failure compared with standard of care Based on this, a phase II, double-blind, multicenter, placebo-controlled study was conducted at multiple clinical centers in China. A total of 351 patients with stable chronic heart failure (NYHA class III or IV) were included in the study. were admitted to hospital and randomized to placebo or rhNRG-1 group (0.6 μg / kg). There were no significant differences in demographics or treatment history between the groups. According to the protocol, patients were administered the drug for 10 consecutive days in the hospital, with a follow-up on the 11th day. They were subsequently discharged and treated as outpatients once a week from weeks 3 to 25. Blood samples were taken from each patient before (baseline) and at each follow-up visit. NT-proBNP was measured using the T-proBNP measurement method (Biomedica kit). P was examined at the core laboratory. Survival information was collected at week 52 of the study.
[0079] Investigational Drug: Specifications: Neucardin (trademark), molecular weight of 7054 Dal (1 μg = 0.14 nm ol) neuregulin-1 β2 isoform containing the 61 amino acid sequence that contains the EGF-like domain Acid polypeptide. 250μg(5000EU) / vial (1μg=20EU).
[0080] Preparation: For injection.
[0081] Mode of administration: infusion or intravenous infusion.
[0082] Storage: 3-8°C, in a safe place with limited access and no light.
[0083] placebo: Specification: Neucardin™ excipient. 250 μg / vial, active ingredient Does not contain recombinant human neuregulin-1 protein.
[0084] [Table 6]
[0085] Criteria for study participants included relatively stable disease (no clinical signs, symptoms, or symptoms for more than one month) LVE (including those receiving standard treatment for CHF at target or maximum tolerated doses) Patients with CHF (NYHA class III or IV) between 18 and 80 years of age with F less than 40% The main exclusion criteria were: acute myocardial infarction, hypertrophic cardiomyopathy, constrictive pericarditis, severe Valvular or congenital heart disease, severe pulmonary hypertension, systolic blood pressure less than 90mmHg or systolic blood pressure higher than 160 mmHg, severe arrhythmia, or cardiac arrest within the past 6 months Women who had undergone surgery or had a cerebrovascular event, were claustrophobic, or were pregnant were included. All patients signed a consent form.
[0086] All-cause mortality at week 52 in the placebo group was 15.91% (of 176 patients) 28 patients died, whereas the all-cause mortality rate was 9.71% in the rhNRG-1 group. Of the 175 patients who completed the study, 16 died (hazard ratio = 0.425, 95% confidence interval (CI) = 0.01 to 0.05; %CI 0.222-0.813, p=0.0097). Mortality from cardiovascular events Considering the 52-week mortality rate in the placebo group, the mortality rate was 14.77% in 176 patients. Of the 11 patients, 26 died, compared with 9.71% in the rhNRG-1 group. The placebo group continued standard treatment for chronic heart failure, but those who received rhNRG-1 did not. The mortality rate was reduced by about 40% compared to the placebo group.
[0087] All-cause mortality according to baseline NT-proBNP stratification was also analyzed. -proBNP level ≤1600fmol / ml, >1600fmol / ml and below 4000 fmol / ml, or above 4000 fmol / ml. When divided, the mortality rates in the rhNRG-1 group and the placebo group were 1 .49% vs. 8.49%, 8.96% vs. 23.33%, and 26.67% vs. 28.00% NT-proBNP level was 4000 fmol / ml or less, or When stratified by ≥ 100 mg / mL, the prognosis for mortality in the rhNRG-1 group was Mortality in the placebo group was 5.22% vs. 14.89%, respectively (p=0.0092); and 26.67% vs 28.00%. These results suggest that rhNRG-1 may be an effective treatment for patients with chronic heart failure. The results show statistical significance in that the treatment can substantially improve survival in patients with bronchitis.
[0088] In addition, patients were classified into NYHA class III or IV at baseline. Class III all-cause mortality was 6.06% (1 8 deaths among 32 patients) and 15.49% in the placebo group (142 patients) Of these, 22 died (p=0.0189). On the other hand, the all-cause mortality rate in class IV was 20.93% (9 deaths out of 43 patients) in the rhNRG-1 group, 17.65% in the placebo group (6 deaths out of 34 patients) (p=0.7789) It is.
Claims
[Claim 1] 13. A pharmaceutical composition substantially as described herein.
Citation Information
Patent Citations
Neuregulin based methods for treating heart failure
WO2010142141A1
